About Hepatic sodium/bile acid cotransporter
Hepatic sodium/bile acid cotransporter (SLC10A1) is a protein
from Homo sapiens identified by UniProt accession
Q14973, 349 residues long.
MolForge cross-references it against 0 known binders and
121 disease associations.
Target properties
| Protein name | Hepatic sodium/bile acid cotransporter |
| UniProt accession | Q14973 |
| Gene | SLC10A1 |
| Organism | Homo sapiens |
| Length | 349 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (12)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (121)
Diseases linked to this target (Open Targets).
- hypercholanemia, familial, 2 · score 0.70
- hepatitis D virus infection · score 0.41
- viral disease · score 0.38
- hypercholanemia, familial · score 0.37
- chronic hepatitis · score 0.28
- cutaneous melanoma · score 0.15
- hepatitis B virus infection · score 0.12
- hemoglobin measurement · score 0.12
- chronic hepatitis B virus infection · score 0.11
- hepatocellular carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14973-F1 | alphafold | PREDICTED | 83.50 | — |
Amino-acid sequence (349 residues)
MEAHNASAPF NFTLPPNFGK RPTDLALSVI LVFMLFFIML SLGCTMEFSK IKAHLWKPKG LAIALVAQYG IMPLTAFVLG KVFRLKNIEA LAILVCGCSP GGNLSNVFSL AMKGDMNLSI VMTTCSTFCA LGMMPLLLYI YSRGIYDGDL KDKVPYKGIV ISLVLVLIPC TIGIVLKSKR PQYMRYVIKG GMIIILLCSV AVTVLSAINV GKSIMFAMTP LLIATSSLMP FIGFLLGYVL SALFCLNGRC RRTVSMETGC QNVQLCSTIL NVAFPPEVIG PLFFFPLLYM IFQLGEGLLL IAIFWCYEKF KTPKDKTKMI YTAATTEETI PGALGNGTYK GEDCSPCTA
Explore Hepatic sodium/bile acid cotransporter with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets